Detection of miRNAs in HPA Axis Function in Healthy Subjects
NCT04066647
Terminated
The proposed study will test dexamethasone effect on miRNA profile in healthy humans. As our data indicate that miRNA levels change over time, the investigators will study the time course of miRNA response to 1 mg IV dexamethasone within 60 minutes after injection. Dexamethasone is used routinely in human subjects for the treatment of inflammatory conditions and as a diagnostic tool in the evaluation of excess cortisol secretion (Cushing's syndrome). For the latter, 1 mg dexamethasone is given o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2020
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Dexamethasone Effect on miRNA Profile in Healthy Humans
Register for Updates
the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block
NCT02653144
Completed
The purpose of the study is to determine if perineural dexmedetomidine can provide increased prolongation of analgesia when compared to perineural dexamethasone in patients receiving regional block for shoulder surgery. If so, dexmedetomidine may serve as a superior adjunct to peripheral nerve blocks in a rapidly evolving, ambulatory-centered surgical setting.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/08/2020
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Opioid Use, Unspecified
Register for Updates
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
NCT01839487
Completed
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) \[PAG\] to NAB and GEM \[AG\] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PE... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2020
Locations: Alabama Oncology, Birmingham, Alabama +50 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01832727
Terminated
The primary objectives are: Phase 1b: * To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules. * To evaluate safety and tolerability Phase 2: * To estimate the overall response rate (ORR). * To evaluate safety and tolerability
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2020
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +12 locations
Conditions: Multiple Myeloma
Register for Updates
Short Term Corticosteroids in SARS-CoV2 Patients
NCT04445506
Completed
The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2020
Locations: The Miriam Hospital, Providence, Rhode Island
Conditions: Corticosteroids, Covid19, SARS-CoV 2, Steroids, Dexamethasone
Register for Updates
Ketoconazole and Dexamethasone in Prostate Cancer
NCT01036594
Completed
This is an open label, phase II, single center trial of ketoconazole/dexamethasone to determine if the administration of ketoconazole/dexamethasone, after disease progression with ketoconazole/hydrocortisone slows or reverses disease progression in men with progressive prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2020
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer
Register for Updates
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
NCT03889444
Completed
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2020
Locations: Clinical Trials Registry Team, Irvine, California
Conditions: Diabetic Macular Edema
Register for Updates
Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery
NCT02724033
Terminated
The investigators would like to compare the therapeutic and cost effectiveness of established therapies for postoperative nausea and vomiting to regional nerve blocks of the head and neck area an intervention known for analgesia but for which the antiemetic effects hasn't been entirely explored. The rational is based on the knowledge of the anatomical innervation of the inner ear and the role of the parasympathetic nervous system in the emetic act. A lot of focus has been given on its counterpa... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/27/2020
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Anesthesia, Pediatrics, Surgery
Register for Updates
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03492138
Terminated
ONC201 is a novel dopamine receptor D2 antagonist that is able to activate the integrated stress response pathway. It is active against multiple myeloma cells in vitro, both as a single agent and in combination with corticosteroids and proteasome inhibitors. In order to document superiority over the combination compared to the individual agents of ixazomib and ONC201 in a single arm study, there will initially be a run-in period of weekly ONC201 625 mg with dexamethasone 40 mg such that if there... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2020
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
NCT02779283
Completed
This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It also evaluates safety and potential efficacy. Kinase inhibitor is a type of substance that blocks an enzyme called a kinase. Human cells have many different kinase... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/21/2020
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Register for Updates
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00903968
Completed
The purpose of this research study is to determine the safety of plerixafor and bortezomib, and the highest dose that can be given to people safely. Plerixafor appears to stop myeloma cells from attaching to bone marrow and has been used in other phase I studies for mobilization of stem cells for patients with myeloma and lymphoma. We have shown that the combination of plerixafor and bortezomib is very effective in killing myeloma cells in the laboratory more than the effect of each drug alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2020
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +4 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
NCT00290498
Completed
The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma. At this point, all participants will now be assigned to the R-HCVAD arm of the study. Researchers will study the safety and effectiveness of this drug combination.
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
05/18/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates